The Protective Role of Bacteroides fragilis in a Murine Model of Colitis-Associated Colorectal Cancer

• Published in: mSphere Vol. 3; no. 6
• Main Authors: Lee, Yun Kyung, Mehrabian, Parpi, Boyajian, Silva, Wu, Wei-Li, Selicha, Jane, Vonderfecht, Steven, Mazmanian, Sarkis K.
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 14.11.2018
• Subjects: Animal diseases; Animal models; Azoxymethane; Bacteria; Bacteroides fragilis; CCR5 protein; Colitis; Colon cancer; Colonization; Colorectal cancer; Colorectal carcinoma; Cytokines; Dextran; Dextran sulfate; Digestive system; Gastrointestinal tract; Gene expression; Histopathology; Host-Microbe Biology; Inflammation; Inflammatory bowel disease; Inflammatory bowel diseases; Intestinal microflora; Intestine; Microbiota; Pathogenesis; Polysaccharides; Rodents; Sodium; Software; Studies; TLR2 protein; Toll-like receptors; Tumor necrosis factor-TNF; Tumorigenesis; United States > US; California; Bacteroides fragilis; Toll-like receptor 2; inflammation; colitis-associated colorectal cancer; polysaccharide A
• ISSN: 2379-5042; 2379-5042
• DOI: 10.1128/mSphere.00587-18

The incidence of colorectal cancer (CRC) is rapidly growing worldwide, and there is therefore a greater emphasis on studies of the treatment or prevention of CRC pathogenesis. Recent studies suggested that consideration of the microbiota is unavoidable to understand inflammation and tumorigenesis in the gastrointestinal tract. We demonstrate, using a mouse model of colitis-associated CRC, that human commensal B. fragilis protects against colon tumorigenesis. The protective role against tumor formation provided by B. fragilis is associated with inhibition of expression of the chemokine receptor CCR5 in the colon. The molecular mechanism for protection against CRC provided by B. fragilis is dependent on polysaccharide A production and is mediated by TLR2 signaling. Our results suggest that the commensal microorganism B. fragilis can be used to prevent inflammation-associated CRC development and may provide an effective therapeutic strategy for CRC. Many patients with chronic inflammation of the gut, such as that observed in inflammatory bowel disease (IBD), develop colorectal cancer (CRC). Recent studies have reported that the development of IBD and CRC partly results from an imbalanced composition of intestinal microbiota and that intestinal inflammation in these diseases can be modulated by the microbiota. The human commensal Bacteroides fragilis is best exemplified playing a protective role against the development of experimental colitis in several animal disease models. In this study, we found that gut inflammation caused by dextran sulfate sodium (DSS) treatment was inhibited by B. fragilis colonization in mice. Further, we reveal a protective role of B. fragilis treatment against colon tumorigenesis using an azoxymethane (AOM)/DSS-induced model of colitis-associated colon cancer in mice and demonstrate that the decreased tumorigenesis by B. fragilis administration is accompanied by inhibited expression of C-C chemokine receptor 5 (CCR5) in the gut. We show direct evidence that the inhibition of tumor formation provided by B. fragilis in colitis-associated CRC animals was dependent on the production of polysaccharide A (PSA) from B. fragilis and that Toll-like receptor 2 (TLR2) signaling was responsible for the protective function of B. fragilis . IMPORTANCE The incidence of colorectal cancer (CRC) is rapidly growing worldwide, and there is therefore a greater emphasis on studies of the treatment or prevention of CRC pathogenesis. Recent studies suggested that consideration of the microbiota is unavoidable to understand inflammation and tumorigenesis in the gastrointestinal tract. We demonstrate, using a mouse model of colitis-associated CRC, that human commensal B. fragilis protects against colon tumorigenesis. The protective role against tumor formation provided by B. fragilis is associated with inhibition of expression of the chemokine receptor CCR5 in the colon. The molecular mechanism for protection against CRC provided by B. fragilis is dependent on polysaccharide A production and is mediated by TLR2 signaling. Our results suggest that the commensal microorganism B. fragilis can be used to prevent inflammation-associated CRC development and may provide an effective therapeutic strategy for CRC.